And indeed, yes.
Phytecs. The global consortium.
How is phytecs involved with RLS? Based on the leaked documents,Arthur put together an idea and investment proposal for and potential to prospective capitalists to fund RLS?
That would be the most real scenario here.
• A source told me:
“PHYTECS is a private company with no plans to go public, of which I am aware. I need to speak in general terms, but we are planning a multi-pronged research program that would include not only clinical applications of cannabis, but also other herbal agents that affect the endocannabinoid system. Finally, we are also in the midst of pharmaceutical development of a lead product developed by Professor Mechoulam via the FDA.”
• How could Phytecs be involved with RLS? Maybe they are not, I am just speculating, but to put it mildly, Phytecs is a global consortium composed of the world’s leading experts and pioneers in the field on this topic. I won’t argue with you, I will just share information.
•Phytecs
—The global consortium of leading experts and pioneers in the field of endocannabinoid research.
—Lead by the pioneer himself, Dr. Raphael Mechoulam.
—Raphael Mechoulam, Ph.D., Director of Global Research, Chair of Scientific Advisory Board: Dr. Mechoulam is currently with the Institute for Drug Research at the Faculty of Medicine at the Hebrew University in Jerusalem. His research interests are the chemistry and biological activity of natural products and medicinal agents. His main contributions are in the field of the constituents of cannabis and the endogenous cannabinoids found in the brain and the periphery.
—Ethan Russo, Medical Director: Formerly the Senior Medical Advisor to GW Pharmaceuticals. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, and phytocannabinoid-serotonergic and–vanilloid interactions.
—Tony Coelho, Advisory Board: Former six-term United States congressman from California and was House Majority Whip. Coelho was the main author and sponsor of the Americans with Disabilities Act. Also, former chairman and a current board member of the Epilepsy Foundation.
—Dr. Jürg Gertsch, Advisory Board: Co-director of the Institute of Biochemistry and Molecular Medicine at the University of Bern, Switzerland and professor of Membrane Biochemistry.
His current research focuses on molecular pharmacology of the endocannabinoid system and drug discovery. His research group in Bern works on projects related to chemical biology and biochemical pharmacology of lipids, both as basic research and in collaboration with industry.
—Dr. Tamás BĂrĂł, Advisory Board: Professor and Chair of the Department of Immunology at the University of Debrecen in Hungary. Dr. BĂrĂł is also Head of the DE-MTA LendĂĽlet Cellular Physiology Group of the Hungarian Academy of Sciences located at the Department of Physiology at University of Debrecen. Dr. BĂrĂł's current research activities chiefly focus on understanding the regulatory role of the endocannabinoid system and the closely related family of the TRP ion channels in the formation and establishment of the complex (physico-chemical, immunological, and regeneration) barrier of the human skin. Moreover, multiple projects of his Labs aim at exploiting the potential of numerous synthetic and plant-derived molecules, targeting the endocannabinoid system and certain TRP channels, in the therapeutic management of various skin diseases.
—Heather Bradshaw, Ph.D., Advisory Board: is an Associate Professor in the Department of Psychological & Brain Sciences at Indiana University, where she directs the Bradshaw Lab of Lipid Neuroscience. Currently Dr. Bradshaw’s research focus is aimed at lipid signaling at transient receptor potential (TRP) channels and orphan G-protein coupled receptors in the central nervous system and uterus. She is examining disease models of endometriosis, chronic pain, and neuroinflammation and their link to aberrant lipid signaling in the ECS and related mediators.
—Katarzyna Starowicz, Ph.D., Advisory Board: is an Associate Professor in the Department of Pain Pharmacology at Institute of Pharmacology, Polish Academy of Sciences, where she directs the Pain Lab. Dr. Starowicz's interests focus on bridging large gaps in the field of pain neurobiology concerning the pathomechanisms of chronic pain with the aim to pinpoint novel targets for the development of new pain therapies.
www.phytecs.comwww.phytecs.com/about-us/team/www.phytecs.com/about-us/natural-product/•Phytecs is exploring product development derived from its research conducted across the globe: North and South America, Europe and Israel. Phytecs researches compounds and derivatives from plant species to create tomorrow’s medicines. These plants produce compounds that interact with the endocannabinoid system in many different ways, from mimicking endocannabinoids to slowing or accelerating the enzymes that metabolize them.
There is an abundance of plants from cloves to black truffles to spruce trees that produce compounds that interact with the ECS and other associated lipid signaling networks.
•Fluorinated CBD compounds, compositions and uses thereof
—inflammation (none limiting examples include: Crohn's disease, inflammatory bowel disease, colitis, pancreatitis, asthma, chronic inflammatory and neuropathic pain);...
—rheumatoid arthritis;...
—epilepsy and convulsions;...
—In further embodiments, said condition, disease, disorder or symptom associated with inflammation is selected from rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, diabetes and any combinations thereof.
patents.justia.com/patent/9447019•Prof. Raphael Mechoulam has developed a family of fluorinated derivatives of CBD. Adding a fluorine atom to drug molecules often dramatically increases their potency. HUF-101, a fluorinated CBD created by Prof. Mechoulam, was shown in a new study from University of São Paulo to be ten times more potent than CBD. Preliminary toxicology research on HUF-101 indicates that it shares a similar safety profile to ordinary CBD. Phytecs is expanding its research slate to examine the potential in a range of indications for this family of fluorinated cannabinoid variants. Here's a link to the study published in PLOS ONE.
journals.plos.org/plosone/article/asset?id=10.1371%2Fjournal.pone.0158779.PDF•Ethan Russo
—Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
www.phytecs.com/wp-content/uploads/2015/02/Clinical-Endocannabinoid-Deficiency-Reconsidered.pdf•CARYODIOL (Phytecs Trademark)
—PHARMACEUTICAL PREPARATIONS AND SUBSTANCES FOR THE TREATMENT OF CHRONIC PAIN, INFLAMMATION, SUBSTANCE DEPENDENCY, DERMATOLOGICAL CONDITIONS, AUTOIMMUNE DISORDERS, PSYCHIATRIC DISEASES AND DISORDERS, AND CANCERS; PLANT EXTRACTS FOR MEDICAL, VETERINARY AND PHARMACEUTICAL PURPOSES